Endocyte, Inc. (NASDAQ:ECYT)‘s stock had its “hold” rating reissued by analysts at Cowen and Company in a report released on Monday.

ECYT has been the topic of a number of other reports. Zacks Investment Research lowered Endocyte from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. ValuEngine upgraded Endocyte from a “strong sell” rating to a “sell” rating in a report on Monday. Finally, Wedbush downgraded shares of Endocyte from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $8.00 to $2.00 in a research report on Monday, June 5th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $5.25.

Endocyte (ECYT) traded up 51.24% on Monday, reaching $5.49. 53,250,455 shares of the company traded hands. The firm’s market cap is $233.74 million. Endocyte has a 52-week low of $1.17 and a 52-week high of $6.55. The stock has a 50-day moving average price of $1.42 and a 200-day moving average price of $1.83.

Endocyte (NASDAQ:ECYT) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). The company had revenue of $0.01 million during the quarter. Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. During the same quarter in the previous year, the business earned ($0.25) EPS. Analysts anticipate that Endocyte will post ($0.93) earnings per share for the current fiscal year.

WARNING: This report was originally reported by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/10/03/endocyte-inc-ecyt-earns-hold-rating-from-cowen-and-company.html.

A number of institutional investors and hedge funds have recently modified their holdings of ECYT. Stifel Financial Corp grew its holdings in Endocyte by 3.9% during the 1st quarter. Stifel Financial Corp now owns 45,353 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 1,711 shares during the period. Bank of New York Mellon Corp raised its position in shares of Endocyte by 4.7% in the 1st quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock worth $369,000 after acquiring an additional 6,469 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Endocyte by 17.1% in the 4th quarter. Teachers Advisors LLC now owns 65,119 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 9,506 shares in the last quarter. RMB Capital Management LLC raised its position in shares of Endocyte by 8.8% in the 1st quarter. RMB Capital Management LLC now owns 264,885 shares of the biopharmaceutical company’s stock worth $681,000 after acquiring an additional 21,500 shares in the last quarter. Finally, FMR LLC raised its position in shares of Endocyte by 0.7% in the 1st quarter. FMR LLC now owns 3,509,035 shares of the biopharmaceutical company’s stock worth $9,018,000 after acquiring an additional 24,625 shares in the last quarter. 28.80% of the stock is currently owned by institutional investors and hedge funds.

About Endocyte

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.